NEJM editorial calls PRIMA the first treatment to restore vision in geographic atrophy

Science Corporation/PRIMA retinal implant

An editorial in the New England Journal of Medicine described PRIMA as the first treatment in clinical trials to restore functional vision to some patients with geographic atrophy from age-related macular degeneration, a leading cause of blindness. Previous treatments only slowed disease progression rather than reversing vision loss.

• NEJM editorial identifies PRIMA as first treatment restoring functional vision in geographic atrophy trials.
• Geographic atrophy (late-stage AMD) causes irreversible vision loss; previous treatments only slow progression.
• PRIMA uses light-powered subretinal implant with camera glasses; 80% of patients gained meaningful visual improvement.